This year’s GIANT has launched a new conference track to explore how the future of health tech can be financed. Through discussion with the companies tackling today’s health moonshots, and the visionary investors financing them, we will look at how innovation can be accelerated. Bringing together the investment community with start-ups, scale-ups and innovators from across Europe and around the world we will talk about trends, products and business models and provide a productive space for meeting and collaborating.
Why attend?
• The future of health tech innovation depends on visionary entrepreneurs having the resources available to build great
products and great companies.
•Ageing, growing populations, and the increase in chronic illnesses such as obesity and diabetes are not small problems.
They demand efficient new solutions, built in a strong ecosystem, prepared to take some calculated risk.
• Health moonshots require radical collaboration around audacious health goals; we are bringing together investors, startups
and corporate innovators, with the right mindset, a moonshot vision to speed up progress in solving big health challenges,
ensuring access to care and improving the wellbeing of people worldwide
The Bacillus Calmette-Guérin (BCG) vaccine prevents severe forms of tuberculosis (TB) and is the world’s most widely used vaccine, as well as the oldest vaccine still in use.
Read more here.
Cigna's Evernorth is investing $100 million through 2028 in specialty pharmacy care.
The AI program called Pharmacy Forward is expected to generate approximately $400 million in value by the end of 2028, according to Evernorth.
Read more here.